Introducing the Neologicals Platform

Precision Medicine. Engineered at the Molecular Level.

Neologics Bioscience is redefining targeted therapeutics — combining proprietary ligand-receptor science with next-generation delivery mechanisms to address cancers and inflammatory diseases where conventional treatments fail.

10xBinding Affinity Improvement|
87%Tumor Reduction in Preclinical Models|
4Active Pipeline Programs|
60%Off-Target Toxicity Reduction|
3xTherapeutic Window Expansion|
10xBinding Affinity Improvement|
87%Tumor Reduction in Preclinical Models|
4Active Pipeline Programs|
60%Off-Target Toxicity Reduction|
3xTherapeutic Window Expansion|
0
Tumor reduction in preclinical models
Neologicals-001 Phase I data
0
Binding affinity vs. standard of care
Proprietary ligand engineering
0
Reduction in off-target toxicity
Compared to conventional chemotherapy
0
Active pipeline programs
Oncology & inflammatory disease
The Neologicals Platform

A New Class of Targeted Therapeutics

Neologicals is a proprietary molecular targeting platform that engineers high-affinity ligands to selectively bind overexpressed receptors on diseased cells. By coupling these precision ligands with potent therapeutic payloads, Neologicals achieves tumor-selective delivery that spares healthy tissue — dramatically improving the therapeutic index and enabling doses previously impossible with conventional agents.

Mechanism of Action

01
Target Identification
Proprietary algorithms identify receptor overexpression signatures unique to diseased tissue
02
Ligand Engineering
High-affinity ligands are engineered for selective binding with sub-nanomolar precision
03
Payload Conjugation
Therapeutic payloads are conjugated via cleavable linkers for controlled intracellular release
04
Selective Delivery
Neologicals conjugates accumulate in target tissue, minimizing systemic exposure and toxicity
Neologicals platform scientific research
Platform Status
Phase I/II
Neologicals-001 · Active
Drug Pipeline

Programs Advancing Toward the Clinic

Neologicals-001
Advanced Solid Tumors
EGFR-overexpressing cancers
Phase I/II
Neologicals-002
Non-Hodgkin Lymphoma
CD22-targeted B-cell malignancies
IND-Enabling
Neologicals-003
Rheumatoid Arthritis
Synovial macrophage targeting
Preclinical
Neologicals-004
Pancreatic Cancer
Mesothelin-expressing tumors
Discovery
"We are not incrementally improving existing therapies. We are building the molecular architecture for a new era of medicine — one where every treatment is as precise as the disease it targets."
Neologics Bioscience — Scientific Founding Thesis

Ready to invest in the future of medicine?

We are actively seeking strategic investors and research partners to accelerate our pipeline toward clinical milestones. Connect with our team to explore collaboration opportunities.

Neologics Bioscience

Pioneering the next generation of targeted therapeutics through the Neologicals platform — where precision science meets transformative medicine.

Active Research Programs

Get In Touch

Interested in investment opportunities or research partnerships?

Contact Us

© 2026 Neologics Bioscience. All rights reserved. neologicals.com

Disclaimer: The information on this website is for informational purposes only and does not constitute medical advice, investment advice, or a solicitation to invest. SpalRx is an investigational platform and has not been approved by the FDA or any regulatory authority.